2025年3月7日 · Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

2025年3月13日 · Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Over the past 25 years, Novartis has achieved medical breakthroughs in cancer care, heart disease and the fight against inflammatory conditions. We are also strongly committed to giving back to society and harnessing the potential of data and digital.

2025年1月31日 · Learn how Novartis uses science-based innovation to create value over the longer term for our company, our shareholders, and society.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach …

2025年3月7日 · Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.

2025年1月31日 · In the fourth quarter of 2023, net income from discontinued operations amounted to USD 5.8 billion, driven by the IFRS Accounting Standards non-cash, non-taxable, net gain on distribution of Sandoz Group AG to Novartis AG shareholders of USD 5.9 billion.

Novartis Deutschland ist ein weltweit tätiger Konzern mit starkem Patienten- und Kundenfokus. Wir konzentrieren uns auf innovative, verschreibungspflichtige Medikamente.

Novartis in België Onze missie is om innovatieve geneesmiddelen te ontdekken en de levenskwaliteit van de patiënten te verbeteren. Innovatieve geneesmiddelen

2023年12月31日 · Novartis announced the company’s financial results for the first quarter of 2024. Media release (295 KB) Medienmitteilung (323 KB) Communiqué de presse (371 KB) Interim financial report (376 KB)